American Century Companies Inc. Trims Stake in Health Catalyst, Inc. $HCAT

American Century Companies Inc. lowered its holdings in Health Catalyst, Inc. (NASDAQ:HCAT) by 83.4% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 117,974 shares of the company’s stock after selling 592,507 shares during the quarter. American Century Companies Inc. owned 0.17% of Health Catalyst worth $534,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of HCAT. Group One Trading LLC raised its holdings in Health Catalyst by 107.6% in the 4th quarter. Group One Trading LLC now owns 4,360 shares of the company’s stock valued at $31,000 after buying an additional 2,260 shares during the period. XTX Topco Ltd purchased a new stake in shares of Health Catalyst in the 1st quarter valued at approximately $54,000. Brevan Howard Capital Management LP purchased a new stake in shares of Health Catalyst in the 4th quarter valued at approximately $92,000. MCF Advisors LLC purchased a new stake in Health Catalyst in the first quarter valued at approximately $113,000. Finally, ProShare Advisors LLC raised its position in Health Catalyst by 52.7% in the fourth quarter. ProShare Advisors LLC now owns 16,854 shares of the company’s stock valued at $119,000 after purchasing an additional 5,815 shares during the period. 85.00% of the stock is currently owned by hedge funds and other institutional investors.

Health Catalyst Trading Up 2.4%

Shares of Health Catalyst stock opened at $3.38 on Friday. Health Catalyst, Inc. has a 1 year low of $2.52 and a 1 year high of $9.24. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.83 and a current ratio of 1.83. The company has a market capitalization of $237.85 million, a P/E ratio of -2.24 and a beta of 1.53. The company’s fifty day moving average is $3.59 and its two-hundred day moving average is $3.94.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the company. Evercore ISI boosted their price objective on Health Catalyst from $3.00 to $4.00 and gave the company an “in-line” rating in a report on Thursday, August 28th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $4.00 target price (down from $9.00) on shares of Health Catalyst in a research note on Friday, August 8th. Piper Sandler downgraded Health Catalyst from an “overweight” rating to a “neutral” rating and cut their price target for the stock from $8.00 to $4.00 in a report on Wednesday, August 27th. Summit Redstone set a $5.00 price objective on shares of Health Catalyst in a research report on Friday, August 29th. Finally, Canaccord Genuity Group dropped their target price on Health Catalyst from $9.00 to $5.00 and set a “buy” rating on the stock in a report on Friday, August 29th. Three investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat, Health Catalyst presently has a consensus rating of “Hold” and a consensus price target of $4.73.

About Health Catalyst

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.